Femme Homme
- | Pays :
- Greece
- Italy
- Spain
- Les 2 autres...
- | Organes : -
- | Spécialités : -
Extrait
The purpose of this randomized, Phase 2 open-label study was to assess the response rate of participants with Human Epidermal Growth Factor Receptor 2 (Her2+) locally advanced and/or metastatic breast cancer (not previously treated with chemotherapy or trastuzumab) to treatment with ixabepilone plus trastuzumab and/or docetaxel plus trastuzumab.
Critère d'inclusion
- Metastatic breast cancer